DailyIQ
|
Sector:HealthcareAll sectors
Last updated 2 minutes ago

HIMS·Hims & Hers Health, Inc.

$.
+. (+.%)
Pre-Market
High
$24.57
Open
$24.24
Market Cap
5.52B
52W High
$70.43
Low
$24.17
P. Close
$24.30
P/E
43.00
52W Low
$13.74
Fwd P/E
18.54
Mean Target
$26.82
Technical Score (1D)
50
NEUTRAL
News Sentiment
62
BULLISH
A director at Hims & Hers Health recently acquired 48,400 shares, signaling strong management confidence in the company's future prospects. This insider buying activity comes as Bank of America highlights significant challenges in reaching 2026 revenue guidance, primarily due to potential churn within the oral Wegovy subscription model. To meet these projections, HIMS is estimated to need approximately 225,000 new oral Wegovy customers. Investors are closely watching HIMS, with the stock currently trending and drawing increased scrutiny. Bank of America recently adjusted its price target to $25 from $28, though it maintains an 'overweight' rating, with the average analyst price target still above this figure. The market will be looking for updates on customer acquisition strategies and retention efforts for the Wegovy offering.
Earnings Summary
Hims & Hers Health, Inc. operates a telehealth platform focused on direct-to-consumer healthcare services and products, including prescription medications and over-the-counter items for wellness, sexual health, skincare, and hair care. The company operates within the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry, differentiating itself through curated product selections, medical consultations, and personalized health insights via its Labs service. In its most recent reported quarters, Hims & Hers demonstrated a mixed performance. For Q1 2026, the company reported an actual EPS of -0.18 against an estimate of 0.13253, and revenue of $608.1 million against an estimate of $629.19 million, marking a miss on both metrics. This followed a Q4 2025 where actual EPS was 0.07 against an estimate of 0.24889, and revenue was $617.82 million against an estimate of $652.59 million, also a miss on both. Looking at the prior two quarters, Q3 2025 saw actual EPS of 0.06 versus an estimate of 0.1017, and Q2 2025 reported actual EPS of 0.17 against an estimate of 0.16472, indicating a beat. This pattern suggests recent deceleration in EPS performance following a prior beat. Historically, Hims & Hers has shown a variable beat/miss pattern against analyst estimates. For instance, the company beat EPS estimates in Q2 2025 but missed significantly in Q4 2025 and Q1 2026. Revenue estimates were not consistently provided in the earlier quarters, making a full historical revenue trend analysis challenging, though recent quarters show revenue figures generally below estimates. Recent news indicates Hims & Hers is expanding its personalized care platform by integrating laboratory services and launching new hormone therapy programs, alongside initiating global market expansion with the launch of generic semaglutide in Canada. This strategic diversification and international push follow a Q1 earnings miss, with analysts maintaining a cautiously optimistic view and some revising price targets upward. Investors will be watching for the impact of these platform and market expansions on future growth and profitability, particularly the uptake of the Canadian GLP-1 offering and the company's ability to navigate near-term financial pressures from strategic adjustments and margin compression.

EPS

EstBeatMiss
$-0.24$-0.10$0.03$0.17$0.31Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$0.13 - -
Q1'26$0.13$-0.18-235.8%
Q4'25$0.25$0.07-71.9%
Q3'25$0.10$0.06-41.0%
Q2'25$0.16$0.17+3.2%
Q1'25$0.12$0.20+65.0%

Revenue

EstBeatMiss
$521M$573M$624M$675M$727MQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$703M - -
Q1'26$629M$608M-3.4%
Q4'25$653M$618M-5.3%
Q3'25 - $599M -
Q2'25 - $545M -
Q1'25 - $586M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

HIMS Stock Snapshot

HIMS is currently trading at $24.33, giving Hims & Hers Health, Inc. a market cap of 5.52B and a P/E ratio of 43.0. Today's range spans $24.17–$24.57, with shares opening at $24.24 and moving up $0.03 (0.1%) from the prior close. DailyIQ's technical score sits at 50/100 (HOLD) with a news sentiment reading of 62/100.

Over the past year HIMS has traded between $13.74 and $70.43 - the current price is +77.1% off the 52-week low and -65.5% from the high. 25 analysts cover the stock with a Hold consensus and a mean 12-month target of $26.82 (range $21.00–$35.00), implying upside of +10.2%.

Hims & Hers Health, Inc. (HIMS) is a small-cap in Healthcare with 5.52B in market cap - and the current technical read of 50/100 (HOLD) alongside bullish sentiment (62/100) suggests limited near-term institutional demand. Price: $24.33 (in the lower half of its 52-week range). The current P/E ratio stands at 43.0. At this capitalization, thin liquidity means that any change in sentiment can move the stock faster than the signal would suggest. Annual range: $13.74–$70.43.

The absence of strong institutional sponsorship makes HIMS's HOLD signal (50/100) more consequential than the same signal in a larger name — at 5.52B in Healthcare market cap, there are fewer natural buyers to absorb selling pressure, which means the $13.74–$70.43 range's lower bound becomes a sharper test of the thesis. Sentiment at 62/100 (bullish) and price at $24.33 (in the lower half of its 52-week range) don't yet suggest stabilization is imminent.